Chunwei Xu

25PUBLICATIONS
87CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jan 20, 2026
Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Ling Xie, Chunwei Xu, Han Si

|Nov 03, 2025
Epithelial-Mesenchymal Transition States and Metabolic Reprogramming Related Signatures Predict Prognosis and Therapeutic Responses in HER2-Positive Breast Cancer.

Yuhui Zheng, Yinduo Zeng, Mengping Xi

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

|Dec 10, 2023
A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma.

Xiaofeng Li, Chunwei Xu, Yonghua Min

|Nov 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Dingzhi Huang, Gen Lin, Qian Chu

|Sep 18, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.

Xingxiang Pu, Chunwei Xu, Qian Wang

Pageof 5

Frequent Collaborators

13 joint publications

Wenxian Wang

9 joint publications

Yong Song

8 joint publications

Chengzhi Zhou

7 joint publications

Yongchang Zhang